Metraipolis › archive › dc_3cc924c2dcdc
PROTAC-mediated degradation of Bcl-xL potentiates target therapy in preclinical melanoma models — Europe PMC PMID:41501884
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41501884
- DOI
- 10.1186/s13046-[numero omesso]-w
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T23:55:24.359Z
- SHA-256 of the archived text
9d11f21f6da9930f1d1821db0dcaebf8d097073e562c0b118eb452104f82bae4- Stable URL of this page
https://metraipolis.com/documento/dc_3cc924c2dcdc
How to cite
PROTAC-mediated degradation of Bcl-xL potentiates target therapy in preclinical melanoma models — Europe PMC PMID:41501884 — Europe PMC (en), https://europepmc.org/article/MED/41501884 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_3cc924c2dcdc (Metraipolis archive dc_3cc924c2dcdc, sha256 9d11f21f6da9930f1d1821db0dcaebf8d097073e562c0b118eb452104f82bae4)
BibTeX
@misc{dc3cc924c2dcdc,
title = {PROTAC-mediated degradation of Bcl-xL potentiates target therapy in preclinical melanoma models — Europe PMC PMID:41501884},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41501884},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_3cc924c2dcdc; sha256 9d11f21f6da9930f1d1821db0dcaebf8d097073e562c0b118eb452104f82bae4},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41501884. Agents can read the archived copy with the MCP tool read_document.